Important Dates:

• Submission Deadline
• June 15, 2024: Submission deadline for Original Research, Systematic Reviews/Meta-Analyses, Scoping Reviews, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts
• August 15, 2024: Submission deadline for Research-in-Progress abstracts (Students and Residents and Fellows, only)
• Notification of Acceptance
  • August 15, 2024: Authors of Original Research, Systematic Reviews/Meta-Analyses, Scoping Reviews, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts will be notified of acceptance or declination no later than this date.
  • September 1, 2024: Authors of Research-in-Progress (Students, Residents, and Fellows, only) abstracts will be notified of acceptance or declination no later than this date.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit https://www.accp.com/abstracts/2024abstracts/ on the ACCP website. Note: Scoping Reviews is a new abstract category for the 2024 ACCP Annual Meeting. If you are interested in submitting a Scoping Review, please carefully review the evaluation criteria before submission.

All abstracts accepted and presented by the designated presenting author, except for “Encore,” “Research-in-Progress,” and PRN Contributed presentations, will have full-text abstracts published online in JACCP, an official journal of ACCP. Only the abstract title, authors, and original citation will be published for “Encore” presentations. All accepted abstracts will be published full text in the ACCP meeting app.

ABSTRACT CATEGORIES:

Advances in International Clinical Pharmacy Practice, Education, or Training: Abstracts must describe the delivery, justification, documentation, and significance of clinical pharmacy practice, education, or training outside the United States. Abstracts may be descriptive and need not contain an evaluative component.

Case Reports: Abstracts of case reports must update and expand therapeutic insights and possibilities or generate research hypotheses. Although narrative in nature, these abstracts must stress the “evidence” for the authors’ conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient’s case, how the patient was evaluated and treated, and a specific description of the outcome. Encore submissions are also welcome.

Clinical Pharmacy Forum: Abstracts must describe the delivery, justification, documentation, adaptability, and impact/significance of innovative clinical pharmacy services. Abstracts that address CMM (comprehensive medication management) implementation (see www.accp.com/cmm), address components of the ACCP Standards of Practice for Clinical Pharmacists, and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.

Original Research: Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should be relevant to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are invited. Encore submissions are also welcome.

Scoping Reviews: Abstracts must describe a scoping review adhering to the guidelines established by PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Submissions should highlight the objectives, findings, and implications of the review, emphasizing its contribution to knowledge and identifying gaps for further research. (Note: Scoping Reviews are distinct from traditional literature reviews in their broader focus and exploratory nature.)

Systematic Reviews/Meta-Analyses: Abstracts must describe a systematic review adhering to the guidelines and definitions established by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and include the 12 items published in the PRISMA for Abstracts checklist. Encore submissions are also welcome. (Note: Systematic Reviews are not the same as a literature review.)

Residents and Fellows Research-in-Progress: Submission guidelines are the same as for an Original Research abstract except that the research effort is ongoing at the time of abstract submission. The presenting author must be in a postgraduate training program (PGY1 or PGY2 residency, Ph.D./master’s graduate degree program, or fellowship training program).

Students Research-in-Progress: Submission guidelines are the same as for an Original Research abstract, except that the research effort is ongoing at the time of abstract submission. The presenting author must be a first professional degree (Pharm.D. or BSPharm) student.

Encore Presentations: Submission and evaluation criteria are the same as for the Original Research, Systematic Reviews/Meta-Analyses, and Case Reports categories, except that the same abstract was presented elsewhere or published in abstract form only before this meeting. Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change but must be an author on the original abstract.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit https://www.accp.com/abstracts/2023abstracts/ on the ACCP website.